| Pioglitazone use and risk of bladder cancer: population based cohort study M Tuccori, KB Filion, H Yin, HY Oriana, RW Platt, L Azoulay bmj 352, 2016 | 253 | 2016 |
| A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative … RE Kast, JA Boockvar, A Brüning, F Cappello, WW Chang, B Cvek, ... Oncotarget 4 (4), 502, 2013 | 201 | 2013 |
| Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders L Antonioli, R Colucci, C La Motta, M Tuccori, O Awwad, F Da Settimo, ... Current drug targets 13 (6), 842-862, 2012 | 173 | 2012 |
| Cyclophosphamide-methotrexate ‘metronomic’chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation G Bocci, M Tuccori, U Emmenegger, V Liguori, A Falcone, RS Kerbel, ... Annals of oncology 16 (8), 1243-1252, 2005 | 148 | 2005 |
| Convalescent plasma therapy for COVID-19: state of the art D Focosi, AO Anderson, JW Tang, M Tuccori Clinical microbiology reviews 33 (4), 10.1128/cmr. 00072-20, 2020 | 146 | 2020 |
| Monoclonal antibody therapies against SARS-CoV-2 D Focosi, S McConnell, A Casadevall, E Cappello, G Valdiserra, ... The Lancet Infectious Diseases 22 (11), e311-e326, 2022 | 144 | 2022 |
| Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review M Tuccori, A Testi, L Antonioli, M Fornai, S Montagnani, N Ghisu, ... Clinical therapeutics 31, 1426-1453, 2009 | 141 | 2009 |
| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline M Tuccori, S Ferraro, I Convertino, E Cappello, G Valdiserra, C Blandizzi, ... MAbs 12 (1), 1854149, 2020 | 139 | 2020 |
| Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications L Antonioli, M Fornai, R Colucci, N Ghisu, M Tuccori, M Del Tacca, ... Pharmacology & therapeutics 120 (3), 233-253, 2008 | 133 | 2008 |
| Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy R Leone, L Magro, U Moretti, P Cutroneo, M Moschini, D Motola, ... Drug safety 33, 667-675, 2010 | 132 | 2010 |
| COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current … N Luxi, A Giovanazzi, A Capuano, S Crisafulli, PM Cutroneo, MP Fantini, ... Drug safety 44 (12), 1247-1269, 2021 | 117 | 2021 |
| ALK-1–negative anaplastic large cell lymphoma associated with breast implants: A new clinical entity D Lazzeri, T Agostini, G Bocci, G Giannotti, G Fanelli, AG Naccarato, ... Clinical breast cancer 11 (5), 283-296, 2011 | 93 | 2011 |
| The impact of the COVID-19 “Infodemic” on drug-utilization behaviors: implications for pharmacovigilance M Tuccori, I Convertino, S Ferraro, E Cappello, G Valdiserra, D Focosi, ... Drug safety 43, 699-709, 2020 | 89 | 2020 |
| Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: what do we know after 20 years of rituximab D Focosi, M Tuccori, F Maggi Reviews in medical virology 29 (6), e2077, 2019 | 88 | 2019 |
| Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage M Fornai, G Natale, R Colucci, M Tuccori, G Carazzina, L Antonioli, ... Naunyn-Schmiedeberg's archives of pharmacology 372, 79-87, 2005 | 88 | 2005 |
| Drug-induced taste and smell alterations: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting M Tuccori, F Lapi, A Testi, E Ruggiero, U Moretti, A Vannacci, R Bonaiuti, ... Drug safety 34, 849-859, 2011 | 85 | 2011 |
| Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system E Raschi, A Mazzarella, IC Antonazzo, N Bendinelli, E Forcesi, M Tuccori, ... Targeted oncology 14, 205-221, 2019 | 83 | 2019 |
| Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases L Antonioli, M Fornai, R Colucci, N Ghisu, M Tuccori, M Del Tacca, ... Inflammatory bowel diseases 14 (4), 566-574, 2008 | 80 | 2008 |
| Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of … M Fornai, R Colucci, L Antonioli, O Awwad, C Ugolini, M Tuccori, F Fulceri, ... Pharmacological Research 63 (1), 59-67, 2011 | 78 | 2011 |
| Drug therapeutic failures in emergency department patients: a university hospital experience A Franceschi, M Tuccori, G Bocci, F Vannozzi, A Di Paolo, C Barbara, ... Pharmacological research 49 (1), 85-91, 2004 | 76 | 2004 |
Corrado Blandizzi, MDProfessore di Farmacologia, Università di PisaVerified email at med.unipi.it
